Pharmaceuticals

Insilico Medicine's AI-powered drug ISM8969, a brain-penetrant inhibitor, has been cleared by the FDA for clinical trials in Parkinson's disease.

With strong Q1 momentum, Standex faces a complex market. Its upcoming Q2 results will offer key insights into global manufacturing and corporate strategy.

A major clinical trial setback for a promising liver disease drug leaves patients waiting and puts Bausch Health's future strategy under scrutiny.

Acrivon Therapeutics to unveil pivotal data showing high response rates for its targeted drug ACR-368 in an aggressive endometrial cancer subtype.

Ontario's new FAST program provides accelerated funding for two key cancer drugs, cutting patient wait times and setting a new standard for access in Canada.

A single patient with a debilitating eye pain condition gains access to an investigational therapy, offering hope where no approved treatments exist.

Swiss biotech GeNeuro suspends trading, awaiting a critical court ruling on its debt moratorium that will decide its fate and the future of its novel drugs.

As Embecta prepares its Q1 results, investors watch closely to see if its move beyond insulin can reverse recent revenue declines and reshape its future.

London's Ellipses Pharma in-licenses a novel B7H3 antibody-drug conjugate from Innolake, aiming to outmaneuver competitors with a unique payload.

With $287M in new funding, Corxel Pharmaceuticals aims to disrupt the obesity market with its oral GLP-1 drug, CX11, and a diverse cardiometabolic pipeline.

A new partnership embeds programmatic ads into electronic health records, promising hyper-targeted marketing but raising questions about clinical disruption.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

Ski champion Lindsey Vonn leverages her Olympic comeback to partner with biopharma firm Invivyd, aiming to educate Americans on antibody-based disease prevention.

A new global consortium aims to break the antibiotic R&D logjam, using open science and AI to combat the growing superbug crisis threatening millions.

Simulations Plus reveals its new AI-driven ecosystem, aiming to solve pharma's biggest R&D hurdles with a focus on regulatory trust and integration.

India's 'Vaccine Capital' unveils a bold new policy at Davos, shifting from manufacturing to high-value innovation to join the world's top life sciences hubs.

The deal merges BlueRidge's broad life sciences support with Design Science's niche expertise in usability, a critical and mandatory field for FDA approval.

With over $100 million in economic benefits locked in, Montréal's strategic planning secures its place as a top global convention hub for the next decade.

An investigational drug from Veloxis Pharmaceuticals has received a key FDA designation, offering new hope for liver transplant patients facing lifelong toxic therapies.

A new therapy for a rare blood cancer gets a major boost from the FDA, offering hope for thousands of myelofibrosis patients with limited options.